According to FutureWise analysis the market for antibody drug conjugate in 2023 was US$ 10.50 billion, and is expected to reach US$ around 26.68 billion by 2031 at a CAGR of 16.6%.
Antibody-drug conjugates (ADCs) mark a significant breakthrough in the realm of targeted biopharmaceutical therapies. These innovative therapeutics combine monoclonal antibodies, which selectively identify surface antigens on specific tumor cells, with potent anti-cancer agents that are linked via a chemical connector. The design of ADCs entails complexity and necessitates meticulous consideration of several critical components. Key factors include the selection of the specific target antigen, the choice of monoclonal antibody (mAb), the cytotoxic payload, and the methodology of linking the antibody to the drug. These elements are pivotal in determining the safety and efficacy of ADCs. The unique targeting capabilities of antibodies facilitate precise differentiation between healthy and malignant tissues, while the cytotoxic drugs deliver the requisite cell-killing action.
Antibodies are specialized glycoproteins that the immune system produces in response to foreign substances. Monoclonal antibodies (mAbs) are generated by the cloning of a specific white blood cell or progenitor cell, resulting in antibodies that exhibit monovalent affinity, which allows them to bind to a particular region of an antigen known as an epitope or antigenic determinant. Polyclonal antibodies, on the other hand, identify several epitopes and are generated by a variety of antibody cell lineages.
FutureWise Market Research has published a report that provides an insightful analysis of Antibody Drug Conjugate Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10050&type=requestsample
Antibody Drug Conjugate Market Segmentation:
By Type
- Monoclonal Antibodies
- Linker
- Drug/Toxin
- Others
By Application
- Leukemia
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Prostate Cancer
- Kidney Cancer
- Pancreas Cancer
- Ovary Cancer
- Glioblastoma
- Lung Cancer
- Colon Cancer
- Breast Cancer
- Skin Cancer
- Solid Tumors
- Multiple Myeloma
- Lymphoma
By Product
- Adcetris
- Kadcyla
- Others
By Technology
- ImmunoGen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Others
By End User
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biopharmaceutical Companies
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Antibody Drug Conjugate Market:
- Seattle Genetics
- ImmunoGen, Inc.
- Roche Holding AG
- Genentech
- Concortis Biotherapeutics
- AGENSYS, INC.
- Antikor
- Immunomedics
- Pfizer Inc.
- Celldex Therapeutics
- Millennium Pharmaceuticals
- AbbVie Inc.
- Bayer HealthCare
- Astellas Pharma/Agensys
- Progenics Pharmaceuticals
- Mersana Therapeutics
- Synthon
- Heidelberg Pharma
- Oxford BioTherapeutics
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10050&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
